

CITATION REPORT

List of articles citing

Efficacy of sildenafil citrate at 12 hours after dosing:
re-exploring the therapeutic window

DOI: 10.1016/j.eururo.2004.04.025

European Urology, 2004, 46, 357-60; discussion 360-1.

Source: <https://exaly.com/paper-pdf/36884737/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
58	Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies. <i>Current Urology Reports</i> , 2004 , 5, 451-9	2.9	8
57	Current World Literature. <i>Current Opinion in Urology</i> , 2005 , 15, 410-415	2.8	
56	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). <i>International Journal of Clinical Practice</i> , 2005 , 59, 680-91	2.9	61
55	The efficacy of tadalafil in clinical populations. <i>Journal of Sexual Medicine</i> , 2005 , 2, 517-31	1.1	56
54	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 848-55	1.1	30
53	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. <i>Urologic Clinics of North America</i> , 2005 , 32, 419-29, vi	2.9	34
52	The European Organisation for Research and Treatment of Cancer: a unique pan-European network. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 141-5	4	2
51	Editorial comment on the manuscript entitled VComparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunctionV <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1-2	4	2
50	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , 2005 , 65, 1621-50	12.1	133
49	Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. <i>Urology</i> , 2006 , 68, 689-96	1.6	27
48	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 689-702	64.1	366
47	EAU Guidelines on erectile dysfunction: an update. <i>European Urology</i> , 2006 , 49, 806-15	10.2	204
46	Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 323, 730-7	4.7	20
45	Phosphodiesterase type 5 inhibitorsVextended duration of response as a variable in the treatment of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007 , 19, 119-23	2.3	27
44	Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007 , 19, 154-60	2.3	23
43	Sildenafil in the treatment of erectile dysfunction. <i>Aging Health</i> , 2007 , 3, 295-303		2
42	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2.3	33

41	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1850-62	2.9	27
40	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	10.2	73
39	Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. <i>Journal of Sexual Medicine</i> , 2007 , 4, 137-144	1.1	9
38	Modulation of the NO/cGMP pathway reduces the vasoconstriction induced by acellular and PEGylated haemoglobin. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008 , 1784, 1428-34	4	5
37	Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. <i>Urology</i> , 2008 , 71, 686-92	1.6	17
36	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <i>Circulation: Heart Failure</i> , 2008 , 1, 272-80	7.6	43
35	Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction. <i>International Journal of Impotence Research</i> , 2008 , 20, 388-95	2.3	4
34	Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. <i>International Journal of Impotence Research</i> , 2008 , 20, 333-42	2.3	37
33	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H1398-H1406	5.2	90
32	Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S420-2	14.6	7
31	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. <i>European Urology</i> , 2009 , 56, 1067-73	10.2	15
30	Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. <i>Journal of Sexual Medicine</i> , 2010 , 7, 2209-2216	1.1	20
29	Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. <i>Molecular Pharmacology</i> , 2010 , 77, 670-7	4.3	18
28	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. <i>Pharmacological Reviews</i> , 2010 , 62, 525-63	22.5	677
27	An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. <i>Nature Reviews Urology</i> , 2010 , 7, 603-9	5.5	41
26	Inhibidores de la fosfodiesterasa 5: calidad de la erección y repercusión emocional en los varones con disfunción eréctil y sus parejas. <i>Revista Internacional De Andrología</i> , 2010 , 8, 155-164	0.6	2
25	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10
24	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. <i>Physiological Reviews</i> , 2011 , 91, 651-90	47.9	443

23	Udenafil for the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 341-54	2.9	16
22	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
21	Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. <i>Urological Science</i> , 2016 , 27, 66-70	0.3	7
20	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , 2016 , 13, 465-88	1.1	110
19	Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men. <i>Clinical Drug Investigation</i> , 2018 , 38, 765-772	3.2	12
18	Mental Health and Sexual Medicine: An Update. 2019 , 347-371		
17	Contemporary Vistas in Geriatric Sexuality. <i>Journal of Psychosexual Health</i> , 2019 , 1, 215-221	0.9	3
16	Erectile Dysfunction: A Primer for in Office Management. <i>Medical Sciences (Basel, Switzerland)</i> , 2019 , 7,	3.3	
15	Sexual Dysfunction and Infertility. 2019 , 47-56		
14	Sildenafil and tadalafil reduce the risk of contrast-induced nephropathy by modulating the oxidant/antioxidant balance in a murine model. <i>Food and Chemical Toxicology</i> , 2020 , 135, 111038	4.7	16
13	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 821-834	4	3
12	Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
11	A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021 , 93, 221-226	1.6	6
10	Optimum Use of Second Line Treatment Options for Erectile Dysfunction. 2017 , 157-177		1
9	Erectile Dysfunction: Pharmacological Therapy. 2011 , 675-696		1
8	Modulating cGMP to treat lung diseases. <i>Handbook of Experimental Pharmacology</i> , 2009 , 469-83	3.2	8
7	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 403-14	4	36
6	PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. 2015 , 185-193		

5	Erectile Dysfunction. 2015 , 65-116	
4	Sex and Pharmacological Sexual Enhancement. 2017 , 387-411	
3	Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers.	o
2	Avanafil: The Second-Generation Treatment of Erectile Dysfunction. 61-69	o
1	Current trends in pharmacotherapy of erectile dysfunction. 2023 , 37, 5-9	o